BRAF and colorectal carcinoma: Best results were obtained in symptomatic patients and BRAF-mutated mCRC; an outstanding ORR of 71% in BRAF-mutated CRC vs. 22% in BRAF-WT was observed, although these data did not reach statistical significance, again due to the small number of patients [55].